Physician profile
Martin Escobar
NPI 1730166117
$2,541.07
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,526 · 2020: $15.32.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $661.73 | 2019-2020 | |
| Daiichi Sankyo INC. | $576.82 | 2019 | |
| Gilead Sciences, INC. | $269.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $225.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $156.13 | 2019 | |
| Allergan, INC. | $152.22 | 2019 | |
| Novo Nordisk INC | $123.01 | 2019 | |
| Abbvie INC. | $86.64 | 2019 | |
| Pfizer INC. | $65.61 | 2019 | |
| Mdd US Operations, LLC | $60.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.05 | 2019 | |
| Sentynl Therapeutics, INC. | $19.17 | 2019 | |
| Shionogi INC | $17.45 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.37 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.50 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $15.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.83 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.47 | 2019 | |
| Lilly USA, LLC | $12.39 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Escobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.